Increased spine bone density in patients with chronic hepatitis B switched to tenofovir alafenamide : A prospective, multinational study
© 2023 John Wiley & Sons Ltd..
BACKGROUND: Data on patients switched to tenofovir alafenamide (TAF) from nucleos(t)ide analogues (NUCs) other than tenofovir disoproxil fumarate are limited.
AIMS: To assess the treatment and renal/bone safety outcomes following the switch to TAF.
METHODS: We prospectively enrolled adult patients with chronic hepatitis B (CHB) who switched from any NUC to TAF at 14 centres in Japan, Korea, Taiwan and the U.S. Study outcomes were viral suppression (VR; HBV DNA < 20 IU/mL), biochemical response (BR; alanine aminotransferase normalisation), and changes in estimated glomerular filtration rate (eGFR) and T-scores (L-spine) by bone absorptiometry by 24 months after switch to TAF.
RESULTS: We enrolled 270 eligible patients. Mean age was 58.1; 58.2% were male; 12.2% had cirrhosis and 73.3% previously received entecavir monotherapy. VR rate increased significantly from 95.2% to 98.8% by 24 months after the switch to TAF (p = 0.014). Between the switch and 24 months later, the mean spine T-score improved significantly from -1.43 ± 1.36 to -1.17 ± 1.38 (p < 0.0001), while there was no significant change in mean eGFR (88.4 ± 16.9-89.5 ± 16.3 mL/min/1.73 m2 , p = 0.13). On multivariable analysis adjusted for age, sex, baseline spine T-score and prior TDF or adefovir dipivoxil use, male sex was significantly associated with lower risk of worsening spine T-score (odds ratio: 0.29, p = 0.020), while age was significantly associated with a higher risk of worsening chronic kidney disease stage (OR: 1.07, p = 0.019).
CONCLUSIONS: At 24 months after the switch to TAF, VR rates and spine bone density improved significantly while renal function remained stable.
| Errataetall: |
ErratumIn: Aliment Pharmacol Ther. 2024 Jan 19;:. - PMID 38240626 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:59 |
|---|---|
| Enthalten in: |
Alimentary pharmacology & therapeutics - 59(2024), 2 vom: 25. Jan., Seite 239-248 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ogawa, Eiichi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
99YXE507IL |
|---|
| Anmerkungen: |
Date Completed 29.12.2023 Date Revised 19.01.2024 published: Print-Electronic ErratumIn: Aliment Pharmacol Ther. 2024 Jan 19;:. - PMID 38240626 Citation Status MEDLINE |
|---|
| doi: |
10.1111/apt.17785 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363743855 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363743855 | ||
| 003 | DE-627 | ||
| 005 | 20240119231916.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/apt.17785 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1264.xml |
| 035 | |a (DE-627)NLM363743855 | ||
| 035 | |a (NLM)37882252 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ogawa, Eiichi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Increased spine bone density in patients with chronic hepatitis B switched to tenofovir alafenamide |b A prospective, multinational study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.12.2023 | ||
| 500 | |a Date Revised 19.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: Aliment Pharmacol Ther. 2024 Jan 19;:. - PMID 38240626 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 John Wiley & Sons Ltd. | ||
| 520 | |a BACKGROUND: Data on patients switched to tenofovir alafenamide (TAF) from nucleos(t)ide analogues (NUCs) other than tenofovir disoproxil fumarate are limited | ||
| 520 | |a AIMS: To assess the treatment and renal/bone safety outcomes following the switch to TAF | ||
| 520 | |a METHODS: We prospectively enrolled adult patients with chronic hepatitis B (CHB) who switched from any NUC to TAF at 14 centres in Japan, Korea, Taiwan and the U.S. Study outcomes were viral suppression (VR; HBV DNA < 20 IU/mL), biochemical response (BR; alanine aminotransferase normalisation), and changes in estimated glomerular filtration rate (eGFR) and T-scores (L-spine) by bone absorptiometry by 24 months after switch to TAF | ||
| 520 | |a RESULTS: We enrolled 270 eligible patients. Mean age was 58.1; 58.2% were male; 12.2% had cirrhosis and 73.3% previously received entecavir monotherapy. VR rate increased significantly from 95.2% to 98.8% by 24 months after the switch to TAF (p = 0.014). Between the switch and 24 months later, the mean spine T-score improved significantly from -1.43 ± 1.36 to -1.17 ± 1.38 (p < 0.0001), while there was no significant change in mean eGFR (88.4 ± 16.9-89.5 ± 16.3 mL/min/1.73 m2 , p = 0.13). On multivariable analysis adjusted for age, sex, baseline spine T-score and prior TDF or adefovir dipivoxil use, male sex was significantly associated with lower risk of worsening spine T-score (odds ratio: 0.29, p = 0.020), while age was significantly associated with a higher risk of worsening chronic kidney disease stage (OR: 1.07, p = 0.019) | ||
| 520 | |a CONCLUSIONS: At 24 months after the switch to TAF, VR rates and spine bone density improved significantly while renal function remained stable | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a bone density | |
| 650 | 4 | |a entecavir | |
| 650 | 4 | |a hepatitis B virus | |
| 650 | 4 | |a sequential therapy | |
| 650 | 4 | |a tenofovir alafenamide | |
| 650 | 7 | |a Alanine |2 NLM | |
| 650 | 7 | |a OF5P57N2ZX |2 NLM | |
| 650 | 7 | |a Tenofovir |2 NLM | |
| 650 | 7 | |a 99YXE507IL |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Jun, Dae Won |e verfasserin |4 aut | |
| 700 | 1 | |a Toyoda, Hidenori |e verfasserin |4 aut | |
| 700 | 1 | |a Hsu, Yao-Chun |e verfasserin |4 aut | |
| 700 | 1 | |a Yoon, Eileen L |e verfasserin |4 aut | |
| 700 | 1 | |a Ahn, Sang Bong |e verfasserin |4 aut | |
| 700 | 1 | |a Yeh, Ming-Lun |e verfasserin |4 aut | |
| 700 | 1 | |a Do, Son |e verfasserin |4 aut | |
| 700 | 1 | |a Trinh, Huy N |e verfasserin |4 aut | |
| 700 | 1 | |a Takahashi, Hirokazu |e verfasserin |4 aut | |
| 700 | 1 | |a Enomoto, Masaru |e verfasserin |4 aut | |
| 700 | 1 | |a Kawada, Norifumi |e verfasserin |4 aut | |
| 700 | 1 | |a Yasuda, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Tseng, Cheng-Hao |e verfasserin |4 aut | |
| 700 | 1 | |a Kawashima, Keigo |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Han Ah |e verfasserin |4 aut | |
| 700 | 1 | |a Inoue, Kaori |e verfasserin |4 aut | |
| 700 | 1 | |a Haga, Hiroaki |e verfasserin |4 aut | |
| 700 | 1 | |a Do, Ai-Thien |e verfasserin |4 aut | |
| 700 | 1 | |a Maeda, Mayumi |e verfasserin |4 aut | |
| 700 | 1 | |a Hoang, Joseph H |e verfasserin |4 aut | |
| 700 | 1 | |a Cheung, Ramsey |e verfasserin |4 aut | |
| 700 | 1 | |a Ueno, Yoshiyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Eguchi, Yuichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Furusyo, Norihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Ming-Lung |e verfasserin |4 aut | |
| 700 | 1 | |a Tanaka, Yasuhito |e verfasserin |4 aut | |
| 700 | 1 | |a Nguyen, Mindie H |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Alimentary pharmacology & therapeutics |d 1992 |g 59(2024), 2 vom: 25. Jan., Seite 239-248 |w (DE-627)NLM012692506 |x 1365-2036 |7 nnns |
| 773 | 1 | 8 | |g volume:59 |g year:2024 |g number:2 |g day:25 |g month:01 |g pages:239-248 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/apt.17785 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 59 |j 2024 |e 2 |b 25 |c 01 |h 239-248 | ||